Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
New research shows patients lose trust and confidence in doctors that take money for travel, but like it when their doctors are paid as consultants during the development of new products.
The future of U.S. health care will be about precision and parsimony. And Roche Diagnostics Corp. think its new line of DNA-level testing machines are just what the doctor ordered.
New tests have helped Roche Diagnostics grow its North American revenue, excluding its troubled diabetes care business, 23 percent over the past five years. But the money for diagnostic tests continues to go down in key areas, noted CFO Wayne Burris.
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
It’s no secret the growth of the U.S. economy slowed in the 2000s after the go-go decade preceding it. But the U.S. health care system—hospitals, doctors, drug companies, device makers and health insurers—apparently didn’t get that memo.
More than half of the $2.5 trillion consumers spend annually on health care in the United States flows to hospitals and doctors, with drug companies and health insurers trailing well behind.
Roche’s diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
Roche Diagnostics Corp. in Indianapolis ranks 89th on the magazine’s latest “Best Companies to Work For” list and was the only Indiana-based company selected.
Roche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.
Roche Diagnostics Corp. plans to eliminate about 80 information technology jobs at its Indianapolis-area campus over the next two years, the company said Thursday morning.
Roche Diagnostics Corp.’s North American business, which is headquartered in Indianapolis, posted a 4-percent boost in sales last year on the strength of its fluid analyzer business unit, even though its diabetes sales fell.
The OK for a new blood glucose monitor comes more than two years after FDA officials declined to approve a previous version of the Nano, which in rare cases generated inflated blood sugar readings because it did not distinguish properly between the sugars glucose and maltose.
It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.
A Hamilton Superior Court judge awarded damages to the local supermarket chain in a soured sublease deal it signed with Roche Diagnostics in March 2008.
Roche Diagnostics will partner with a San Diego firm to incorporate its continuous glucose monitoring sensor with a wireless handheld device Roche is developing to help diabetics test their blood sugar and track their glucose levels throughout the day.
Executives at Roche Diagnostics expect the wave of austerity measures being taken by western governments—including the United States—to as much as double its sales of fluid- and DNA-based tests in the next three years.
New drug for metastatic melanoma packaged with genetic test should help Roche sell more of its cobas 4800 laboratory testing systems.
